Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00788255 · ClinicalTrials.gov registry record
In-vitro Study to Assess the Coagulation Effects of Exogenous Oxytocin Using Thromboelastography.
A clinical trial, sponsored by Stanford University.
- Completed
- Registry status
- 25
- Enrollment target
NCT00788255: Completed study, sponsored by Stanford University.
NCT00788255 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00788255 has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
Study Summary
Oxytocin is normally administered following delivery in pregnant patients to reduce postpartum bleeding by increasing uterine tone. It is unclear whether the use of intravenous oxytocin alters coagulation in pregnant patients. The purpose of the in-vitro study is to assess the coagulation changes of oxytocin in blood samples from pregnant patients using thromboelastrography (TEG). TEG is a point-of-care device which measures the viscoelastic properties of clot formation, and can provide rapid and detailed information about coagulation changes. We aim to collect blood samples from pregnant patients to assess the in-vitro effects of synthetic oxytocin on coagulation using TEG.
Interventions
- DRUG Final exogenous oxytocin concentration=22.5 μU/mL
- DRUG Final exogenous oxytocin concentration=30.1μU/mL
- DRUG Final exogenous oxytocin concentration=32.9μU/mL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2008-10 |
| Est. Completion | 2009-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00788255
The ClinicalTrials.gov registry entry for NCT00788255 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Final exogenous oxytocin concentration=22.5 μU/mL is the first listed.
NCT00788255 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00788255 about?
NCT00788255 is a clinical study titled "In-vitro Study to Assess the Coagulation Effects of Exogenous Oxytocin Using Thromboelastography.". Oxytocin is normally administered following delivery in pregnant patients to reduce postpartum bleeding by increasing uterine tone. It is unclear whether the use of intravenous oxytocin alters coagulation in pregnant patients. The purpose of the in-vitro study is to assess the coagulation changes of...
What is the current status of trial NCT00788255?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2008-10. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00788255?
The interventions under investigation include: Final exogenous oxytocin concentration=22.5 μU/mL (DRUG), Final exogenous oxytocin concentration=30.1μU/mL (DRUG), Final exogenous oxytocin concentration=32.9μU/mL (DRUG).
Who is sponsoring clinical trial NCT00788255?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.